IDev Launches Supera Veritas Stent Delivery System in Europe

May 18, 2010—IDev Technologies, Inc. (Houston, TX) announced the European launch of the Supera Veritas peripheral vascular system. The Supera Veritas is a stent delivery system designed to deliver the company's Supera self-expanding, interwoven nitinol stent for treating biliary and peripheral artery disease. The Supera Veritas delivery system was designed to complement the flexible Supera stent in treating obstructive arterial disease in the superficial femoral artery.

“We have been utilizing the Supera stent clinically for more than 2 years, and we are very impressed with the performance of the stent and the positive clinical outcomes,” commented Professor Dierk Scheinert, MD. “It represents a significant advancement in stent technology, and its unique characteristics allow physicians to treat areas in which standard ‘slotted-tube' nitinol stents have always encountered difficulty. It significantly reduces the number of steps needed to prepare and deliver the stent, all of which greatly increase its ease of use and accuracy.”

In the United States, the Supera stent system has received US Food and Drug Administration 510(k) clearance for palliative treatment of biliary strictures produced by malignant neoplasms. The device is currently being studied in the prospective, single-arm SUPERB clinical trial of 258 patients at up to 40 sites in the United States, the company stated.